{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:47:13Z","timestamp":1778662033808,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jneuroim.2021.577507","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T11:00:57Z","timestamp":1612004457000},"page":"577507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["An interdependence between GAPVD1 gene polymorphism, expression level and response to interferon beta in patients with multiple sclerosis"],"prefix":"10.1016","volume":"353","author":[{"given":"Bahareh","family":"Khademi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Khorrami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hormoz","family":"Ayromlou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Rikhtegar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan Aghaei","family":"Moghadam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahsa","family":"Tahmasebivand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyyed Reza","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Kheirollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Fakhr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Alizadeh-Ghodsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Emamalizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2021.577507_bb0005","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1352458507076990","article-title":"Neutralizing antibody (NAb) assays in multiple sclerosis patients receiving interferon-\u03b2 therapy","volume":"13","author":"Deisenhammer","year":"2007","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-59745-528-2_2","article-title":"OLIGO 7 primer analysis software","volume":"402","author":"Rychlik","year":"2007","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0020","doi-asserted-by":"crossref","first-page":"a011205","DOI":"10.1101\/cshperspect.a011205","article-title":"The Jak\/STAT pathway","volume":"4","author":"Harrison","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0025","first-page":"19","article-title":"Pharmacogenetic biomarkers to predict treatment response in multiple sclerosis: current and future perspectives","volume":"6198530","author":"Coyle","year":"2017","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162752","article-title":"Occurrence of anti-drug antibodies against interferon-Beta and Natalizumab in multiple sclerosis: a collaborative cohort analysis","volume":"11","author":"Bachelet","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0035","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.tig.2017.09.004","article-title":"The genetics of multiple sclerosis: from 0 to 200 in 50 years","volume":"33","author":"Baranzini","year":"2017","journal-title":"Trends Genet."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10072-013-1616-1","article-title":"Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian multiple sclerosis study group","volume":"35","author":"Bertolotto","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cytogfr.2014.10.008","article-title":"Pharmacogenomics of interferon-beta in multiple sclerosis: what has been accomplished and how can we ensure future progress?","volume":"26","author":"Carlson","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/FPC.0000000000000182","article-title":"Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics","volume":"26","author":"Chan","year":"2016","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0055","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.biochi.2007.03.014","article-title":"Interfering with interferon receptor sorting and trafficking: impact on signaling","volume":"89","author":"Claudinon","year":"2007","journal-title":"Biochimie"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1875036201206010055","article-title":"Primer1: primer design web service for tetra-primer ARMS-PCR","volume":"6","author":"Collins","year":"2012","journal-title":"The Open Bioinformatics Journal"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0065","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/tpj.2012.41","article-title":"Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies","volume":"12","author":"Foti Cuzzola","year":"2012","journal-title":"The Pharmacogenomics Journal"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0070","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/1352458506070968","article-title":"Qualitative and quantitative analysis of antibody response against IFN\u03b2 in patients with multiple sclerosis","volume":"12","author":"Gilli","year":"2006","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0075","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/tra.12570","article-title":"Regulation of early endosomes across eukaryotes: evolution and functional homology of Vps9 proteins","volume":"19","author":"Herman","year":"2018","journal-title":"Traffic"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0080","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.3892\/etm.2017.4410","article-title":"Multiple sclerosis: pathology, diagnosis and treatments","volume":"13","author":"Huang","year":"2017","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0085","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bbrc.2005.12.099","article-title":"Rab5-activating protein 6, a novel endosomal protein with a role in endocytosis","volume":"340","author":"Hunker","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0090","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/iub.1530","article-title":"Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-beta therapy","volume":"68","author":"Karam","year":"2016","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0095","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s10038-019-0639-8","article-title":"Full sequence of mutant huntingtin 3\u2032-untranslated region and modulation of its gene regulatory activity by endogenous microRNA","volume":"64","author":"Kim","year":"2019","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062540","article-title":"Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients","volume":"8","author":"Lopez-Gomez","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0105","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.autrev.2013.10.012","article-title":"Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature","volume":"13","author":"Mahurkar","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0110","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/tpj.2016.20","article-title":"Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study","volume":"17","author":"Mahurkar","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0115","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2183\/pjab.94.017","article-title":"Post-transcriptional regulation of immune responses by RNA binding proteins","volume":"94","author":"Mino","year":"2018","journal-title":"Proceedings of the Japan Academy. Series B, Physical and biological sciences"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0120","article-title":"A pharmacogenetic study implicates NINJ2 in the response to interferon-beta in multiple sclerosis","volume":"21","author":"Peroni","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0125","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12026-012-8273-y","article-title":"Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers","volume":"52","author":"Pravica","year":"2012","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0135","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2174\/138920011795495268","article-title":"The role and impact of SNPs in pharmacogenomics and personalized medicine","volume":"12","author":"Rachel","year":"2011","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0140","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/1352458509104591","article-title":"Measures in the first year of therapy predict the response to interferon beta in MS","volume":"15","author":"Rio","year":"2009","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.jneuroim.2021.577507_bb4000","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ana.20224","article-title":"Defining interferon beta response status in multiple sclerosis patients","volume":"56","author":"Rudick","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0145","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/ane.12269","article-title":"Prediction of response to interferon therapy in multiple sclerosis","volume":"130","author":"Sellebjerg","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0150","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1083\/jcb.200806016","article-title":"Coordinated regulation of AP2 uncoating from clathrin-coated vesicles by rab5 and hRME-6","volume":"183","author":"Semerdjieva","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-1331.2008.02264.x","article-title":"Neutralizing antibodies against interferon beta: fluctuation is modest and titre dependent","volume":"16","author":"Sominanda","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0160","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1468-1331.2007.01769.x","article-title":"Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy","volume":"14","author":"Hesse","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577507_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577212","article-title":"miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta","volume":"342","author":"Tahmasebivand","year":"2020","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/FPC.0000000000000194","article-title":"Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs","volume":"26","author":"Tsareva","year":"2016","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.jneuroim.2021.577507_bb0175","first-page":"2211","article-title":"PCBP2 post-transcriptionally regulates sortilin expression by binding to a C-rich element in its 3\u2019 UTR","volume":"21","author":"Yabe-Wada","year":"2020","journal-title":"FEBS Open Bio"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821000345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821000345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:37:54Z","timestamp":1759048674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572821000345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":36,"alternative-id":["S0165572821000345"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577507","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An interdependence between GAPVD1 gene polymorphism, expression level and response to interferon beta in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577507"}}